公开(公告)号：US09522125B1

公开(公告)日：2016-12-20

申请号：US14945436

申请日：2015-11-19

Applicant: Macau University of Science and Technology

Inventor： Xiao-Jun Yao ,  Lai-Han Leung ,  Lian-Xiang Luo ,  Wen-Luan Hsiao ,  Liang Liu

IPC: A61K31/136

CPC classification number: A61K31/136

Abstract: The present invention discloses that a method of treating cancer, preferably non-small cell lung cancer, comprises administrating mitoxantrone. The present invention also discloses a method of inhibiting ROS1 kinase comprising administrating mitoxantrone. A pharmaceutical composition comprising mitoxantrone is also disclosed.

Abstract translation: 本发明公开了一种治疗癌症，优选非小细胞肺癌的方法，包括给予米托蒽醌。 本发明还公开了抑制ROS1激酶的方法，其包括施用米托蒽醌。 还公开了包含米托蒽醌的药物组合物。

公开(公告)号：US09018196B2

公开(公告)日：2015-04-28

申请号：US14251664

申请日：2014-04-14

Applicant: Macau University of Science and Technology

Inventor： Liang Liu ,  Ting Li ,  Fenggen Yan

IPC: A61K31/353 ,  A61K31/573

CPC classification number: A61K31/353 ,  A61K31/573 ,  A61K2300/00

Abstract: This invention provides a method of preventing and/or treating thymus degeneration comprising administering an effective amount of dihydromyricetin to a subject in need thereof, in which the degeneration is induced by dexamethasone. In one embodiment, the thymus degeneration is induced during the course of treatment of inflammation by dexamethasone.

Abstract translation: 本发明提供了一种预防和/或治疗胸腺变性的方法，包括向有需要的受试者施用有效量的二氢黄芪素，其中由地塞米松引起变性。 在一个实施方案中，在用地塞米松治疗炎症过程中诱导胸腺变性。

公开(公告)号：US10702500B2

公开(公告)日：2020-07-07

申请号：US16257018

申请日：2019-01-24

Applicant: Macau University of Science and Technology

Inventor： Xiao Jun Yao ,  Lai Han Elaine Leung ,  Liang Liu ,  Qian Qian Wang ,  Jia Hui Xu ,  Ying Li

IPC: A61K31/4045 ,  A61K45/06 ,  G01N33/574 ,  A61P35/00 ,  C12Q1/48

Abstract: One embodiment is a method of treating cancer. The method includes administering a therapeutically effective amount of a compound to a patient. The compound is represented by Formula I:

公开(公告)号：US20190070170A1

公开(公告)日：2019-03-07

申请号：US15695304

申请日：2017-09-05

Applicant: Macau University of Science and Technology

Inventor： Hua Zhou ,  Jian-Xin Liu ,  Jin-Fang Luo ,  Chun-Song Chen ,  Elaine Lai-Han Leung ,  Liang Liu

IPC: A61K31/485 ,  G01N33/573 ,  C12Q1/68

Abstract: A method of selectively inhibiting the overexpression of mPGES-1 in a subject in need thereof includes a step of administering an effective amount of a selective mPGES-1 inhibitor or a salt thereof to the subject. A method of treating a subject suffering from a disease associated with an overexpression of mPGES-1 and having a risk of cardiovascular event includes the step of administering an effective amount of a selective mPGES-1 inhibitor to the subject.

公开(公告)号：US20180125906A1

公开(公告)日：2018-05-10

申请号：US15345842

申请日：2016-11-08

Applicant: Macau University of Science and Technology

Inventor： Hua Zhou ,  Quanbing Han ,  Yihan Zuo ,  Liang Liu ,  Ruiqi Yue

IPC: A61K36/258 ,  A61K31/715

CPC classification number: A61K36/258 ,  A61K31/715

Abstract: Methods of treating a subject suffering from an ischemic condition and of preventing an ischemia-reperfusion injury in a subject suffering from an ischemic condition, particularly, but not exclusively ischemic heart disease and the subject is in particular a human, includes administering an effective amount of a carbohydrate composition extracted from Panax ginseng to the subject. The carbohydrate composition of the present invention extracted from Panax ginseng shows exceptional cardio-protective effect and, thus, provides a highly advantageous and highly promising treatment option for treatment of ischemic conditions and prevention of ischemia-reperfusion injury. The present invention further provides a method of protecting cells against hypoxia and reoxygenation induced cell death. Still further, the present invention provides a carbohydrate composition extracted from Panax ginseng and a pharmaceutical formulation comprising it.

公开(公告)号：US20180085413A1

公开(公告)日：2018-03-29

申请号：US15280136

申请日：2016-09-29

Applicant: Macau University of Science and Technology

Inventor： Yuen Kwan Law ,  Kam Wai Wong ,  An Gao Wu ,  Liang Liu ,  Zeng Wu

IPC: A61K36/25 ,  A61K31/704 ,  A61K31/56

CPC classification number: A61K36/25 ,  A61K31/19 ,  A61K31/56 ,  A61K31/704 ,  A61K2236/33 ,  A61K2236/35 ,  A61K2236/39 ,  A61P25/28

Abstract: A method for treating a subject suffering from a neurodegenerative disease includes administering at least one triterpenoid which can be obtained from Hedera helix. A method for treating a subject suffering from a neurodegenerative disease includes administering an effective amount of a Hedera helix extract which comprises the triterpenoid. The neurodegenerative disease is preferably but not exclusively Parkinson's disease or Huntington's disease. Methods for extracting the triterpenoid from Hedera helix and a method for inducing autophagy in cells by contacting them with the triterpenoid are also provided. The triterpenoid allows an exceptional induction of autophagy, in particular a significant reduction of the protein level of mutant huntingtin, a significant reduction of the protein level of A53T α-synuclein, a significant inhibition of the oligomerization of α-synuclein and a significant inhibition of the inclusion formation of huntingtin via the AMPK-mTOR dependent autophagy inducing pathway.

公开(公告)号：US09901566B1

公开(公告)日：2018-02-27

申请号：US15401250

申请日：2017-01-09

Applicant: Macau University of Science and Technology

Inventor： Liang Liu ,  Ting Li ,  Guoyuan Zhu ,  Fen Yang

IPC: A61K31/365

CPC classification number: A61K31/365

Abstract: A method of treating a subject, in particular a human, suffering from an autoimmune disease, preferably but not exclusively selected from systemic lupus erythematosus, multiple sclerosis or rheumatoid arthritis includes the step of administering an effective amount of a limonoid to the subject. The present invention further relates to methods of inhibiting the differentiation of T helper 17 cells, T helper 1 cells, T helper 2 cells and/or regulatory T cells and a method of screening substances for their inhibition of one or more of T helper 17 cell, T helper 1 cell, T helper 2 cell and/or regulatory T cell differentiation that may be used to treat an autoimmune disease. This invention provides highly advantageous and promising treatment options for autoimmune diseases, namely for attenuating inflammatory lymphocyte function.

公开(公告)号：US09884047B1

公开(公告)日：2018-02-06

申请号：US15632407

申请日：2017-06-26

Applicant: Macau University of Science and Technology

Inventor： Xiao Jun Yao ,  Lai Han Elaine Leung ,  Liang Liu ,  Xing Xing Fan ,  Chun Xie

IPC: A61K31/428 ,  G01N33/574 ,  C07D277/72 ,  C07K14/47 ,  C12Q1/68 ,  G01N33/68 ,  A61K38/00

CPC classification number: A61K31/428 ,  A61K38/00 ,  C07D277/72 ,  C07K14/47 ,  C07K2319/00 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  G01N33/574 ,  G01N33/57423 ,  G01N33/57484 ,  G01N33/68

Abstract: One example embodiment relates to a method of treating non-small cell lung cancer by administering a compound of formula (I) to a patient. Another example embodiment relates to a method of inhibiting progress of tumor growth in a patient with cancer, wherein tumor cells of the cancer have a mutant V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) gene, and the method includes administering to the patient the compound with the following formula I:

公开(公告)号：US09808477B2

公开(公告)日：2017-11-07

申请号：US14848358

申请日：2015-09-09

Applicant: Macau University of Science and Technology

Inventor： Wen-zhe Ma ,  Sen-ling Feng ,  Xiao-jun Yao ,  Zhong-wen Yuan ,  Liang Liu ,  Ying Xie

IPC: A61K31/352 ,  A61K31/337 ,  A61K45/06 ,  A61K31/704

CPC classification number: A61K31/366 ,  A61K31/337 ,  A61K31/352 ,  A61K31/704 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention discloses a pharmaceutical composition of treating multidrug resistance cancer, comprising a citrus methoxyflavone and a chemotherapeutic drug, in which the citrus methoxyflavone is nobiletin. A method of treating multidrug resistance cancer comprising administrating citrus methoxyflavone and a chemotherapeutic drug is also disclosed.

公开(公告)号：US20170151212A1

公开(公告)日：2017-06-01

申请号：US14953860

申请日：2015-11-30

Applicant: Macau University of Science and Technology

Inventor： Kam Wai Wong ,  Yuen Kwan Law ,  Thomas Efferth ,  Onat Kadioglu ,  Liang Liu

IPC: A61K31/352 ,  A61K31/337 ,  A61K31/704

CPC classification number: A61K31/352 ,  A61K31/337 ,  A61K31/704 ,  A61K2300/00

Abstract: Prenylated isoflavones are suitable to specifically inhibit P-glycoprotein in multidrug-resistant cancer cells leading to an accumulation of cytotoxic compounds or therapeutic compounds in the cells while having exceptionally increased cytotoxic activity specifically towards multidrug-resistant cancer cells and while allowing for an increased activity of chemotherapeutic compounds towards which the cells are resistant.Also in accordance with the present invention is a method for specifically targeting cancer cells with multidrug-resistance as well as a method of potentiating the activity of a chemotherapeutic compound in multidrug-resistant cancer cells. In a further aspect, a kit including a prenylated isoflavone and a chemotherapeutic compound is provided.